We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+33.72%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$783M
AUM Growth
+$288M
Cap. Flow
+$190M
Cap. Flow %
24.26%
Top 10 Hldgs %
60.08%
Holding
55
New
12
Increased
17
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$54M
2
ARRY
Array Biopharma Inc
ARRY
+$38.5M
3
TSRO
TESARO, Inc.
TSRO
+$29.3M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$21.5M
5
PCRX icon
Pacira BioSciences
PCRX
+$17.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$20.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$20.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$16.7M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 75.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$1.52B
– –
-125,000
Closed -$3.29M
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-170,000
Closed -$20.8M
IMMU
53
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-300,800
Closed -$23K
BDSI
54
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-644,176
Closed -$1.13M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Avoro Capital Advisors held 55 positions worth $783M, up 58% from $495M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors deployed $190M of net new capital in Q1 2017, opening 12 new positions and adding to 17 existing holdings. Its largest new stake was Medicines Co: 1,185,000 shares worth $57.9M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier.

On the sell side, the largest reduction was NeuroDerm Ltd. Ordinary Shares, an estimated $11.6M trimmed.

  • Avoro Capital Advisors's largest Q1 2017 buy was Medicines Co: 1,185,000 shares worth $57.9M.
  • Avoro Capital Advisors added most to Array Biopharma Inc in Q1 2017, an estimated $38.5M increase.
  • Avoro Capital Advisors's biggest Q1 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $11.6M.
  • Avoro Capital Advisors fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $27.7M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $783M portfolio in Q1 2017.
  • Avoro Capital Advisors opened 12 new positions and closed 10 in Q1 2017.
  • Avoro Capital Advisors's portfolio value rose 58% quarter-over-quarter to $783M.

Based on Avoro Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.